Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Maletzki, Claudia ^a   Stier, Saskia ^a   Gruenert, Ulrike ^a   Gock, Michael ^a   Ostwald, Christiane ^a   Prall, Friedrich ^a   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; GEMCITABINE; GLYCOPROTEIN; IRINOTECAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL INVASION; CELL LINE HROC113; CELL LINE HROC24; CELL LINE HROC87; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIPLOIDY; DRUG RESPONSE; DRUG SENSITIVITY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; HEREDITARY NONPOLYPOSIS COLORECTAL CARCINOMA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MISMATCH REPAIR; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC COLORECTAL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CYTOKINES; DNA MISMATCH REPAIR; FEMALE; HUMANS; MICE; NEOPLASM INVASIVENESS; PHENOTYPE; PLOIDIES; TREATMENT OUTCOME;

EID: 84871748026     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052485     Document Type: Article

References (37)

1. Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, et al. (2000) Validation of a model of colon cancer progression. J Pathol 192: 446-454.
2. Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9: 4227-4239. Review.
3. Ostwald C, Linnebacher M, Weirich V, Prall F, (2009) Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol 35: 321-327.
4. Harrison S, Benziger H (2011) The molecular biology of colorectal carcinoma and its implications: a review. Surgeon 9: 200-210. Review.
5. Pritchard CC, Grady WM (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60: 116-129. Review.
6. Kang GH, (2011) Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med 135: 698-703.
7. Kim ST, Lee J, Park SH, Park JO, Lim HY, et al. (2010) Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 66: 659-667.
8. Bass A, (2011) Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer. J Clin Oncol 29: 2728-2729.
9. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, et al. (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998.
10. Ku JL, Shin YK, Kim DW, Kim KH, Choi JS, et al. (2010) Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis 31: 1003-1009.
11. Danes BS, Deangelis P, Traganos F, Melamed MR, Alm T, (1988) Demonstration of altered cellular DNA content distribution in long-term colon epithelial cell lines with colon cancer genotypes. Scand J Gastroenterol 23: 840-846.
12. Bocsi J, Zalatnai A, (1999) Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability in morphology, DNA ploidy and proliferation activity. J Cancer Res Clin Oncol 125: 9-19.
13. Poupon MF, Arvelo F, Goguel AF, Bourgeois Y, Jacrot M, et al. (1993) Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 85: 2023-2029.
14. Fielding LP, Arsenault PA, Chapuis PH, Dent O, Gathright B, et al. (1991) Clinocpatholgoical staging for colorectal cancer: an International Documentation System (IDS) and an Interantional Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 6: 325-344.
15. Findeisen P, Kloor M, Merx S, Sutter C, Woerner SM, et al. (2005) T25 repeat in the 3′ untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res 65: 8072-8078.
16. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, et al. (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90-96.
17. Klier U, Maletzki C, Klar E, Linnebacher M, (2010) Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells. Langenbecks Arch Surg 395: 365-371.
18. Jaster R, Lichte P, Fitzner B, Brock P, Glass A, et al. (2005) Peroxisome proliferator-activated receptor gamma overexpression inhibits pro-fibrogenic activities of immortalised rat pancreatic stellate cells. J Cell Mol Med 9: 670-682.
19. Ramer R, Hinz B, (2008) Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 100: 59-69.
20. Tognon M, Casalone R, Martini F, De Mattei M, Granata P, et al. (1996) Large T antigen coding sequences of two DNA tumor viruses, BK and SV40, and nonrandom chromosome changes in two glioblastoma cell lines. Cancer Genet Cytogenet 90: 17-23.
21. Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, et al. (2010) Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer 10: 362.
22. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A, (2010) Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 7: 197-208.
23. Kirkland SC, Bailey IG, (1986) Establishment and characterisation of six human colorectal adenocarcinoma cell lines. Br J Cancer 53: 79-85.
24. Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, et al. (2007) Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 67: 398-407.
25. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, et al. (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18: 5314-28.
26. Gagos S, Iliopoulos D, Tseleni-Balafouta S, Agapitos M, Antachopoulos C, et al. (1996) Cell senescence and a mechanism of clonal evolution leading to continuous cell proliferation, loss of heterozygosity, and tumor heterogeneity: studies on two immortal colon cancer cell lines. Cancer Genet Cytogenet 90: 157-165.
27. Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY, et al. (2011) Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch 459: 55-63.
28. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, et al. (2011) BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes. PLoS One 6: 25806.
29. Ogino S, Shima K, Meyerhardt J, McCleary N, Ng K, et al. (2012) Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. Clin Cancer Res 18: 890-900.
30. Swanton C, Caldas C, (2009) Molecular classification of solid tumors: towards pathway-driven therapeutics. Br J Cancer 100: 1517-22.
31. Castellanos E, Berlin J, Cardin DB (2011) Current treatment options for pancreatic carcinoma. Curr Oncol Rep 13: 195-205. Review.
32. Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, et al. (2012) Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs 30: 772-778.
33. Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, et al. (2012) Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer 130: 1577-1589.
34. Saif MW, Kaley K, Penney R, Hotchkiss S, Syrigos KN, et al. (2011) The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. Anticancer Res 31: 2971-2974.
35. O'Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, et al. (2010) Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 65: 625-39.
36. Hector S, Rehm M, Schmid J, Kehoe J, McCawley N, et al. (2012) Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy. Gut 61: 725-733.
37. Baguley BC, Marshall ES, Finlay GJ, (1999) Short-term cultures of clinical tumor material: potential contributions to oncology research. Oncol Res 11: 115-124.